SlideShare a Scribd company logo
Myocardial Infarction
By
Chiranjeevi Pudi
V Pharm D (2013-14)
CLASSIFICATION
• Acute coronary syndromes include
ST-elevation MI (STEMI)
Non ST-elevation MI ( NSTEMI)
Unstable Angina
PREVALENCE
• In the US, 1.3 million cases of nonfatal MI were
reported in 2006
• Incidence of 600 per 100,000 people
• Increase in the proportion of NSTEMI compared
to STEMI
• Approximately 500,000 to 700,000 deaths are
caused by heart disease
HISTORY
The history is critical in making the diagnosis of
MI and sometimes provide only the only clues
that lead to the diagnosis in the initial phase of
presentation Chest Pain- anterior precordium
tightness
• Pain may radiate to jaw, neck and epigastrium
• Dyspnea- angina equivalent, poor LV function
• Nausea/abdominal pain with posterior MI
• Anxiety
HISTORY
• Nausea with and without vomiting
• Diaphoresis or sweating
• Syncope
• Elderly present with MS changes, fatigue,
syncope or weakness
• As many as half of MI are clinically silent
CAUSES
• Most frequent cause is rupture of an
atherosclerotic lesion within coronary wall with
subsequent spasm and thrombus formation
• Coronary artery vasospasm
• Ventricular hypertrophy
• Hypoxia
• Coronary artery emboli
RISK FACTORS FOR
ATHEROSCLEROSIS
• Age
• Smoking
• Hypercholesterolemia and triglyceridemia
• Diabetes Mellitus
• Poorly controlled hypertension
• Family History
• Sedentary lifestyle
PATHOPHYSIOLOGY
Mechanisms of Myocardial damage
The severity of an MI is dependent of three factors
• The level of the occlusion in the coronary
• The length of time of the occlusion
• The presence or absence of collateral circulation
CARDIAC BIOMARKERS
• Cardiac biomarkers are protein molecules
released into the blood stream from damaged
heart muscle
• Since ECG can be inconclusive , biomarkers are
frequently used to evaluate for myocardial injury
• These biomarkers have a characteristic rise and
fall pattern
Troponin T and I
• These isoforms are very specific for cardiac
injury
• Preferred markers for detecting myocardial cell
injury
• Rise 2-6 hours after injury
Peak in 12-16 hours
Stay elevated for 5-14 days
Creatinine Kinase ( CK-MB)
• Creatinine Kinase is found in heart muscle (MB),
skeletal muscle (MM), and brain (BB)
• Increased in over 90% of myocardial infraction
• However, it can be increased in muscle trauma,
physical exertion, post-op, convulsions, and other
conditions
CK-MB
• Time sequence after myocardial infarction
Begins to rise 4-6 hours
Peaks 24 hours
returns to normal in 2 days
• MB2 released from heart muscle and converted
to MB1.
• A level of MB2 > or = 1 and a ratio of MB2/MB1
> 1.5 indicates myocardial injury
MYOGLOBIN
• Damage to skeletal or cardiac muscle release
myoglobin into circulation
• Time sequence after infarction
Rises fast 2hours
Peaks at 6-8 hours
Returns to normal in 20-36 hours
• Have false positives with skeletal muscle injury
and renal failure
CBC
•CBC is indicated if anemia is suspected as
precipitant
•Leukocytosis may be observed within several
hours after myocardial injury and returns to levels
within the reference range within one week
C-reactive Protein (CRP)
• C- reactive protein is a marker of acute
inflammation
• Patients without evidence of myocardial necrosis
but with elevated CRP are at increased risk of an
event
Release of cardiac markers after acute
myocardial infarction (AMI)
CHEST X-RAY
• Chest radiography may provide clues to an
alternative diagnosis ( aortic dissection or
pneumothorax)
• Chest radiography also reveals complications of
myocardial infarction such as heart failure
ECG
• An ECG can be used to detect patterns of
ischemia, injury, and infarction
Ischemia
• On the ECG, myocardial ischemia results in T-
wave inversion or ST segment depression in the
leads facing the ischemic area.
• The inverted T wave representative of ischemia is
symmetrical, relatively narrow, and somewhat
pointed.
Injury
• the injury process begins in the subendocardial
layer and moves throughout the thickness of the
wall of the heart like a wave.
• If the process is not interrupted, it eventually
results in a transmural MI.
• On ECG, the hallmark of acute myocardial injury
is the presence of ST segment elevations.
• With an acute injury, the ST segments in the
leads facing the injured area are elevated.
• The elevated ST segments also have a downward
concave or coved shape and merge unnoticed
with the T wave
(A)ST segment elevation
without T-wave
inversion.
(B) ST segment elevation
with T-wave inversion.
The elevated ST
segments have a
downward concave or
coved shape and merge
unnoticed with the T
wave.
INFARCTION When myocardial injury persists, MI is the
result.
• During the earliest stage of MI, known as the hyperacute
phase, the T waves become tall and narrow. This
configuration is referred to as hyperacute or peaked T waves.
• Within a few hours, these hyperacute T waves invert.
• Next, the ST segments elevate, a pattern that usually lasts from
several hours to several days.
• In addition to the ST segment elevations in the leads of the
ECG facing the injured heart, the leads facing away from the
injured area may show ST segment depression.
• This finding is known as reciprocal ST segment changes.
• Reciprocal changes are most likely to be seen at the onset of
infarction, but their presence on the ECG does not last long.
• Reciprocal ST segment depressions may simply be a mirror
image of the ST segment elevations.
Therapy
The goals of therapy in AMI
are the expedient restoration of
normal coronary flow and the
maximum salvage of
functional myocardium
Antiplatelet Agents
• Aspirin at least 160–162 mg on hospital day 1
Followed by 75–162 mg daily starting hospital day 2
and continued indefinitely.
• Interferes with function of cyclooxygenase and
inhibits the formation of thromboxane
• Clopidogrel is also used which acts through a
blockade of ADP receptors on platelets
• 300–600 mg loading dose on hospital day 1
followed by a maintenance dose of 75 mg PO qd
starting on hospital day 2 Administer indefinitely in
patients with an aspirin allergy.
Nitrates
• Nitrates promote the release of nitric oxide from the
endothelium, which results in venous and arterial
vasodilation
• Vasodilatation reduces myocardial oxygen demand
and preload and afterload
• 0.4 mg , repeated every 5 min × 3 doses
• 5 to 10 mcg/min by continuous infusion titrated up to
75 to 100 mcg/min until relief of symptoms or
limiting side effects headache or hypotension
• most significant adverse effects - tachycardia,
flushing, headache, and hypotension. Nitrate
• CI - sildenafil and vardenafil within the past 24 hours
and tadalifil within the past 48 hours.
Supplemental Oxygen
• Because MI impairs the circulatory function of
the heart, oxygen extraction by the heart and
other tissues may be diminished
• Supplemental oxygen should be administered to
patient with symptoms and or signs of pulmonary
edema or pulse oximetry readings less than 90%.
Unfractionated heparin
• Forms a chemical complex with antithrombin III
inactivates both free thrombin and factor Xa
• Recommended in patients with MI who undergo PTCA
or fibrinolytic therapy with alteplase
Low-molecular weight heparin
• Direct activity against factors Xa and IIa
• Proven to be effective in treating ACS that are
characterized by unstable angina or non ST- elevation MI
• Their fixed doses are easy to administer and laboratory
testing to measure their therapeutic effect is not necessary
makes them attractive alternative of un-fractionated
heparin
Beta-blockers
• Recommended within 12 hours of MI symptoms
and continued indefinitely
• Reduces Myocardial mortality by decreasing
arrythmogenic death
• Decrease the rate and force of myocardial
contraction and decreases overall oxygen demand
Thrombolytics
• Thrombolytic drugs lyse coronary thrombi by
converting plasminogen to plasmin.
• Thrombolytic therapy provides maximal benefit if
given within the first 3 hours after the onset of
symptoms.
• Significant benefit still occurs if therapy is given up to
12 hours after onset of symptoms.
Thrombolytics
• As a class the plasminogen activators have been
shown to restore coronary blood flow in 50-80%
of patients
• Contraindication active intracranial bleeding,
CNS neoplasm, HTN, coagulopathy
• Intracranial bleed risk major drawback
Glycoprotein IIb/IIIa
Antagonists
• Potent inhibitors of platelet aggregation
• Use during PCI and in patients with high risk
features ACS have been shown to reduce the
composite end points of death, reinfraction and
the need for target lesion
Revascularization:
Percutanous Coronary Intervention
• Alternative if performed by skilled operator in an experienced
center
• Standard is a “ door to balloon” time of 90 minutes
• PCI can successfully restore coronary blood flow in 90 to 95%
of MI patients
• PCI definitive survival advantage over fibrinolytics for MI
patients who are in cardiogenic shock
Stenting
•A stent is introduced into a blood vessel on a balloon catheter
and advanced into the blocked area of the artery
• the balloon is then inflated and causes the stent to expand until
it fits the inner wall of the vessel, conforming to contours as
needed
• the balloon is then deflated and drawn back
•The stent stays in place permanently, holding the vessel open
and improving the flow of blood.
Angioplasty
• a balloon catheter is passed through the guiding catheter to the area
near the narrowing. A guide wire inside the balloon catheter is then
advanced through the artery until the tip is beyond the narrowing.
• the angioplasty catheter is moved over the guide wire until the balloon
is within the narrowed segment.
• balloon is inflated, compressing the plaque against the artery wall
• once plaque has been compressed and the artery has been sufficiently
opened, the balloon catheter will be deflated and removed.
Bypass surgery
 healthy blood vessel is removed from leg, arm or chest
 blood vessel is used to create new blood flow path in your heart
 the “bypass graft” enables blood to reach your heart by flowing
around (bypassing) the blocked portion of the diseased artery. The
increased blood flow reduces angina and the risk of heart attack.
Lipid Management
• All post MI patients should be on AMA step II
diet ( < 7% of calories from saturated fats)
• Post MI patients with LDL > 100 mg/dl are
recommended to be on drug therapy to try to
lower levels to <100 mg/dl
• Recent data indicate that all MI patients should
be on statin therapy, regardless of lipid levels
or diet
Long term Medications
• Most oral medications instituted in the hospital at
the time of MI are continued long term
• Aspirin, beta blockers and statin are continued
indefinitely
• ACEI indefinitely in patients with CHF, ejection
fraction <.40, hypertension, or diabetes
Thank you!!

More Related Content

What's hot

Heart failure / cardiac failure
Heart failure / cardiac failureHeart failure / cardiac failure
Heart failure / cardiac failure
Fuad Farooq
 

What's hot (20)

Valvular heart disease
Valvular heart diseaseValvular heart disease
Valvular heart disease
 
Heart block
Heart blockHeart block
Heart block
 
Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial Infarction
 
Heart block
Heart blockHeart block
Heart block
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shock
 
Heart block
Heart blockHeart block
Heart block
 
Cardiac heart failure
Cardiac heart failureCardiac heart failure
Cardiac heart failure
 
Atlas myocardialinfarction
Atlas myocardialinfarctionAtlas myocardialinfarction
Atlas myocardialinfarction
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
Atrial septal defect
Atrial septal defectAtrial septal defect
Atrial septal defect
 
Pericardial effusion
Pericardial effusionPericardial effusion
Pericardial effusion
 
Myocardial infraction sushila
Myocardial infraction sushilaMyocardial infraction sushila
Myocardial infraction sushila
 
VALVULAR HEART DISEASE
VALVULAR HEART DISEASEVALVULAR HEART DISEASE
VALVULAR HEART DISEASE
 
Tricuspid valve disease
Tricuspid valve diseaseTricuspid valve disease
Tricuspid valve disease
 
An Overview of Unstable angina
An Overview of Unstable anginaAn Overview of Unstable angina
An Overview of Unstable angina
 
Heart failure / cardiac failure
Heart failure / cardiac failureHeart failure / cardiac failure
Heart failure / cardiac failure
 
Arrhythmias
ArrhythmiasArrhythmias
Arrhythmias
 
Basics of Electrocardiography(ECG)
Basics of Electrocardiography(ECG)Basics of Electrocardiography(ECG)
Basics of Electrocardiography(ECG)
 
Ischemic Heart Disease
Ischemic Heart DiseaseIschemic Heart Disease
Ischemic Heart Disease
 
Myocardial infarction
Myocardial infarction Myocardial infarction
Myocardial infarction
 

Viewers also liked

Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
adolescent4u
 
Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial Infarction
gdriven
 
MYOCARDIAL INFARCTION-MANAGEMENT
MYOCARDIAL INFARCTION-MANAGEMENTMYOCARDIAL INFARCTION-MANAGEMENT
MYOCARDIAL INFARCTION-MANAGEMENT
shrinathraman
 
High lights on Sleep physiology
High lights on Sleep physiology High lights on Sleep physiology
High lights on Sleep physiology
Ashraf ElAdawy
 
Perioperative myocardial infarction ppt
Perioperative myocardial infarction pptPerioperative myocardial infarction ppt
Perioperative myocardial infarction ppt
Yogasundaram Sasikumar
 

Viewers also liked (20)

Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial Infarction
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial Infarction
 
Acute Myocardial infarction
Acute Myocardial infarctionAcute Myocardial infarction
Acute Myocardial infarction
 
Coronary Artery Disease, Angina pectoris, Myocardial Infarction
Coronary Artery Disease, Angina pectoris, Myocardial InfarctionCoronary Artery Disease, Angina pectoris, Myocardial Infarction
Coronary Artery Disease, Angina pectoris, Myocardial Infarction
 
Acute Myocardial Infarction
Acute Myocardial InfarctionAcute Myocardial Infarction
Acute Myocardial Infarction
 
MYOCARDIAL INFARCTION-MANAGEMENT
MYOCARDIAL INFARCTION-MANAGEMENTMYOCARDIAL INFARCTION-MANAGEMENT
MYOCARDIAL INFARCTION-MANAGEMENT
 
Treatment of myocardial infarction,past& present
Treatment of myocardial infarction,past& presentTreatment of myocardial infarction,past& present
Treatment of myocardial infarction,past& present
 
non pharmacological treatment for myocardial infarction
non pharmacological treatment for myocardial infarction non pharmacological treatment for myocardial infarction
non pharmacological treatment for myocardial infarction
 
Protocol
ProtocolProtocol
Protocol
 
Treatment of myocardial infarction
Treatment of myocardial infarctionTreatment of myocardial infarction
Treatment of myocardial infarction
 
Sleep Physiology and Disorders Arpit
Sleep Physiology and Disorders  ArpitSleep Physiology and Disorders  Arpit
Sleep Physiology and Disorders Arpit
 
Nervous system part 3
Nervous system part 3Nervous system part 3
Nervous system part 3
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
 
High lights on Sleep physiology
High lights on Sleep physiology High lights on Sleep physiology
High lights on Sleep physiology
 
myocardial infarction
myocardial infarctionmyocardial infarction
myocardial infarction
 
Perioperative myocardial infarction ppt
Perioperative myocardial infarction pptPerioperative myocardial infarction ppt
Perioperative myocardial infarction ppt
 
Physilogy sleep
Physilogy sleepPhysilogy sleep
Physilogy sleep
 
Ihd
IhdIhd
Ihd
 

Similar to Myocardial Infarction Pathogenesis and Treatment

cadiovascular disorders:d isease models part ii
cadiovascular disorders:d isease models part iicadiovascular disorders:d isease models part ii
cadiovascular disorders:d isease models part ii
twiggypiggy
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
Jen DC
 

Similar to Myocardial Infarction Pathogenesis and Treatment (20)

Myocardialinfarction
Myocardialinfarction Myocardialinfarction
Myocardialinfarction
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
MI.pptx
MI.pptxMI.pptx
MI.pptx
 
Myocardial infraction sushila
Myocardial infraction sushilaMyocardial infraction sushila
Myocardial infraction sushila
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
4 4-2016 myocardial infarction
4 4-2016 myocardial infarction4 4-2016 myocardial infarction
4 4-2016 myocardial infarction
 
Nursing management patient with Myocardial infraction
Nursing management patient with Myocardial infraction Nursing management patient with Myocardial infraction
Nursing management patient with Myocardial infraction
 
Management of MYOCARDIAL INFARCTION_081637.pptx
Management of MYOCARDIAL INFARCTION_081637.pptxManagement of MYOCARDIAL INFARCTION_081637.pptx
Management of MYOCARDIAL INFARCTION_081637.pptx
 
Afshan ali myocardial infarction
Afshan ali myocardial infarctionAfshan ali myocardial infarction
Afshan ali myocardial infarction
 
Afshan ali myocardial infarction
Afshan ali myocardial infarctionAfshan ali myocardial infarction
Afshan ali myocardial infarction
 
Afshan ali myocardial infarction
Afshan ali myocardial infarctionAfshan ali myocardial infarction
Afshan ali myocardial infarction
 
Angina
AnginaAngina
Angina
 
Analysis of various investigations in myocardial infarction.pptx
Analysis of various investigations in myocardial infarction.pptxAnalysis of various investigations in myocardial infarction.pptx
Analysis of various investigations in myocardial infarction.pptx
 
cadiovascular disorders:d isease models part ii
cadiovascular disorders:d isease models part iicadiovascular disorders:d isease models part ii
cadiovascular disorders:d isease models part ii
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
lecture 3 Cardiac alteration
lecture 3 Cardiac alteration lecture 3 Cardiac alteration
lecture 3 Cardiac alteration
 
ACUTE CORONARY SYNDROME.pptx
ACUTE CORONARY SYNDROME.pptxACUTE CORONARY SYNDROME.pptx
ACUTE CORONARY SYNDROME.pptx
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 

Recently uploaded

platelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptxplatelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptx
muralinath2
 
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
Sérgio Sacani
 
Detectability of Solar Panels as a Technosignature
Detectability of Solar Panels as a TechnosignatureDetectability of Solar Panels as a Technosignature
Detectability of Solar Panels as a Technosignature
Sérgio Sacani
 
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
muralinath2
 
Mammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also FunctionsMammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also Functions
YOGESH DOGRA
 
FAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable PredictionsFAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable Predictions
Michel Dumontier
 

Recently uploaded (20)

platelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptxplatelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptx
 
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
Gliese 12 b: A Temperate Earth-sized Planet at 12 pc Ideal for Atmospheric Tr...
 
EY - Supply Chain Services 2018_template.pptx
EY - Supply Chain Services 2018_template.pptxEY - Supply Chain Services 2018_template.pptx
EY - Supply Chain Services 2018_template.pptx
 
PRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATION
PRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATIONPRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATION
PRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATION
 
Detectability of Solar Panels as a Technosignature
Detectability of Solar Panels as a TechnosignatureDetectability of Solar Panels as a Technosignature
Detectability of Solar Panels as a Technosignature
 
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
 
Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...
 
Structures and textures of metamorphic rocks
Structures and textures of metamorphic rocksStructures and textures of metamorphic rocks
Structures and textures of metamorphic rocks
 
word2vec, node2vec, graph2vec, X2vec: Towards a Theory of Vector Embeddings o...
word2vec, node2vec, graph2vec, X2vec: Towards a Theory of Vector Embeddings o...word2vec, node2vec, graph2vec, X2vec: Towards a Theory of Vector Embeddings o...
word2vec, node2vec, graph2vec, X2vec: Towards a Theory of Vector Embeddings o...
 
NuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final versionNuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final version
 
Microbial Type Culture Collection (MTCC)
Microbial Type Culture Collection (MTCC)Microbial Type Culture Collection (MTCC)
Microbial Type Culture Collection (MTCC)
 
Mammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also FunctionsMammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also Functions
 
FAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable PredictionsFAIR & AI Ready KGs for Explainable Predictions
FAIR & AI Ready KGs for Explainable Predictions
 
Topography and sediments of the floor of the Bay of Bengal
Topography and sediments of the floor of the Bay of BengalTopography and sediments of the floor of the Bay of Bengal
Topography and sediments of the floor of the Bay of Bengal
 
NuGOweek 2024 full programme - hosted by Ghent University
NuGOweek 2024 full programme - hosted by Ghent UniversityNuGOweek 2024 full programme - hosted by Ghent University
NuGOweek 2024 full programme - hosted by Ghent University
 
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of LipidsGBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
 
Gliese 12 b, a temperate Earth-sized planet at 12 parsecs discovered with TES...
Gliese 12 b, a temperate Earth-sized planet at 12 parsecs discovered with TES...Gliese 12 b, a temperate Earth-sized planet at 12 parsecs discovered with TES...
Gliese 12 b, a temperate Earth-sized planet at 12 parsecs discovered with TES...
 
Constraints on Neutrino Natal Kicks from Black-Hole Binary VFTS 243
Constraints on Neutrino Natal Kicks from Black-Hole Binary VFTS 243Constraints on Neutrino Natal Kicks from Black-Hole Binary VFTS 243
Constraints on Neutrino Natal Kicks from Black-Hole Binary VFTS 243
 
insect taxonomy importance systematics and classification
insect taxonomy importance systematics and classificationinsect taxonomy importance systematics and classification
insect taxonomy importance systematics and classification
 
GLOBAL AND LOCAL SCENARIO OF FOOD AND NUTRITION.pptx
GLOBAL AND LOCAL SCENARIO OF FOOD AND NUTRITION.pptxGLOBAL AND LOCAL SCENARIO OF FOOD AND NUTRITION.pptx
GLOBAL AND LOCAL SCENARIO OF FOOD AND NUTRITION.pptx
 

Myocardial Infarction Pathogenesis and Treatment

  • 2.
  • 3.
  • 4. CLASSIFICATION • Acute coronary syndromes include ST-elevation MI (STEMI) Non ST-elevation MI ( NSTEMI) Unstable Angina
  • 5.
  • 6.
  • 7.
  • 8. PREVALENCE • In the US, 1.3 million cases of nonfatal MI were reported in 2006 • Incidence of 600 per 100,000 people • Increase in the proportion of NSTEMI compared to STEMI • Approximately 500,000 to 700,000 deaths are caused by heart disease
  • 9. HISTORY The history is critical in making the diagnosis of MI and sometimes provide only the only clues that lead to the diagnosis in the initial phase of presentation Chest Pain- anterior precordium tightness • Pain may radiate to jaw, neck and epigastrium • Dyspnea- angina equivalent, poor LV function • Nausea/abdominal pain with posterior MI • Anxiety
  • 10. HISTORY • Nausea with and without vomiting • Diaphoresis or sweating • Syncope • Elderly present with MS changes, fatigue, syncope or weakness • As many as half of MI are clinically silent
  • 11. CAUSES • Most frequent cause is rupture of an atherosclerotic lesion within coronary wall with subsequent spasm and thrombus formation • Coronary artery vasospasm • Ventricular hypertrophy • Hypoxia • Coronary artery emboli
  • 12.
  • 13. RISK FACTORS FOR ATHEROSCLEROSIS • Age • Smoking • Hypercholesterolemia and triglyceridemia • Diabetes Mellitus • Poorly controlled hypertension • Family History • Sedentary lifestyle
  • 14.
  • 15.
  • 16.
  • 18.
  • 19.
  • 20.
  • 21. Mechanisms of Myocardial damage The severity of an MI is dependent of three factors • The level of the occlusion in the coronary • The length of time of the occlusion • The presence or absence of collateral circulation
  • 22. CARDIAC BIOMARKERS • Cardiac biomarkers are protein molecules released into the blood stream from damaged heart muscle • Since ECG can be inconclusive , biomarkers are frequently used to evaluate for myocardial injury • These biomarkers have a characteristic rise and fall pattern
  • 23. Troponin T and I • These isoforms are very specific for cardiac injury • Preferred markers for detecting myocardial cell injury • Rise 2-6 hours after injury Peak in 12-16 hours Stay elevated for 5-14 days
  • 24. Creatinine Kinase ( CK-MB) • Creatinine Kinase is found in heart muscle (MB), skeletal muscle (MM), and brain (BB) • Increased in over 90% of myocardial infraction • However, it can be increased in muscle trauma, physical exertion, post-op, convulsions, and other conditions
  • 25. CK-MB • Time sequence after myocardial infarction Begins to rise 4-6 hours Peaks 24 hours returns to normal in 2 days • MB2 released from heart muscle and converted to MB1. • A level of MB2 > or = 1 and a ratio of MB2/MB1 > 1.5 indicates myocardial injury
  • 26. MYOGLOBIN • Damage to skeletal or cardiac muscle release myoglobin into circulation • Time sequence after infarction Rises fast 2hours Peaks at 6-8 hours Returns to normal in 20-36 hours • Have false positives with skeletal muscle injury and renal failure
  • 27. CBC •CBC is indicated if anemia is suspected as precipitant •Leukocytosis may be observed within several hours after myocardial injury and returns to levels within the reference range within one week
  • 28. C-reactive Protein (CRP) • C- reactive protein is a marker of acute inflammation • Patients without evidence of myocardial necrosis but with elevated CRP are at increased risk of an event
  • 29. Release of cardiac markers after acute myocardial infarction (AMI)
  • 30. CHEST X-RAY • Chest radiography may provide clues to an alternative diagnosis ( aortic dissection or pneumothorax) • Chest radiography also reveals complications of myocardial infarction such as heart failure
  • 31. ECG • An ECG can be used to detect patterns of ischemia, injury, and infarction Ischemia • On the ECG, myocardial ischemia results in T- wave inversion or ST segment depression in the leads facing the ischemic area. • The inverted T wave representative of ischemia is symmetrical, relatively narrow, and somewhat pointed.
  • 32.
  • 33. Injury • the injury process begins in the subendocardial layer and moves throughout the thickness of the wall of the heart like a wave. • If the process is not interrupted, it eventually results in a transmural MI. • On ECG, the hallmark of acute myocardial injury is the presence of ST segment elevations. • With an acute injury, the ST segments in the leads facing the injured area are elevated. • The elevated ST segments also have a downward concave or coved shape and merge unnoticed with the T wave
  • 34. (A)ST segment elevation without T-wave inversion. (B) ST segment elevation with T-wave inversion. The elevated ST segments have a downward concave or coved shape and merge unnoticed with the T wave.
  • 35. INFARCTION When myocardial injury persists, MI is the result. • During the earliest stage of MI, known as the hyperacute phase, the T waves become tall and narrow. This configuration is referred to as hyperacute or peaked T waves. • Within a few hours, these hyperacute T waves invert. • Next, the ST segments elevate, a pattern that usually lasts from several hours to several days. • In addition to the ST segment elevations in the leads of the ECG facing the injured heart, the leads facing away from the injured area may show ST segment depression. • This finding is known as reciprocal ST segment changes. • Reciprocal changes are most likely to be seen at the onset of infarction, but their presence on the ECG does not last long. • Reciprocal ST segment depressions may simply be a mirror image of the ST segment elevations.
  • 36.
  • 37. Therapy The goals of therapy in AMI are the expedient restoration of normal coronary flow and the maximum salvage of functional myocardium
  • 38.
  • 39.
  • 40. Antiplatelet Agents • Aspirin at least 160–162 mg on hospital day 1 Followed by 75–162 mg daily starting hospital day 2 and continued indefinitely. • Interferes with function of cyclooxygenase and inhibits the formation of thromboxane • Clopidogrel is also used which acts through a blockade of ADP receptors on platelets • 300–600 mg loading dose on hospital day 1 followed by a maintenance dose of 75 mg PO qd starting on hospital day 2 Administer indefinitely in patients with an aspirin allergy.
  • 41. Nitrates • Nitrates promote the release of nitric oxide from the endothelium, which results in venous and arterial vasodilation • Vasodilatation reduces myocardial oxygen demand and preload and afterload • 0.4 mg , repeated every 5 min × 3 doses • 5 to 10 mcg/min by continuous infusion titrated up to 75 to 100 mcg/min until relief of symptoms or limiting side effects headache or hypotension • most significant adverse effects - tachycardia, flushing, headache, and hypotension. Nitrate • CI - sildenafil and vardenafil within the past 24 hours and tadalifil within the past 48 hours.
  • 42. Supplemental Oxygen • Because MI impairs the circulatory function of the heart, oxygen extraction by the heart and other tissues may be diminished • Supplemental oxygen should be administered to patient with symptoms and or signs of pulmonary edema or pulse oximetry readings less than 90%.
  • 43. Unfractionated heparin • Forms a chemical complex with antithrombin III inactivates both free thrombin and factor Xa • Recommended in patients with MI who undergo PTCA or fibrinolytic therapy with alteplase Low-molecular weight heparin • Direct activity against factors Xa and IIa • Proven to be effective in treating ACS that are characterized by unstable angina or non ST- elevation MI • Their fixed doses are easy to administer and laboratory testing to measure their therapeutic effect is not necessary makes them attractive alternative of un-fractionated heparin
  • 44. Beta-blockers • Recommended within 12 hours of MI symptoms and continued indefinitely • Reduces Myocardial mortality by decreasing arrythmogenic death • Decrease the rate and force of myocardial contraction and decreases overall oxygen demand
  • 45. Thrombolytics • Thrombolytic drugs lyse coronary thrombi by converting plasminogen to plasmin. • Thrombolytic therapy provides maximal benefit if given within the first 3 hours after the onset of symptoms. • Significant benefit still occurs if therapy is given up to 12 hours after onset of symptoms.
  • 46. Thrombolytics • As a class the plasminogen activators have been shown to restore coronary blood flow in 50-80% of patients • Contraindication active intracranial bleeding, CNS neoplasm, HTN, coagulopathy • Intracranial bleed risk major drawback
  • 47. Glycoprotein IIb/IIIa Antagonists • Potent inhibitors of platelet aggregation • Use during PCI and in patients with high risk features ACS have been shown to reduce the composite end points of death, reinfraction and the need for target lesion
  • 49. Percutanous Coronary Intervention • Alternative if performed by skilled operator in an experienced center • Standard is a “ door to balloon” time of 90 minutes • PCI can successfully restore coronary blood flow in 90 to 95% of MI patients • PCI definitive survival advantage over fibrinolytics for MI patients who are in cardiogenic shock
  • 50. Stenting •A stent is introduced into a blood vessel on a balloon catheter and advanced into the blocked area of the artery • the balloon is then inflated and causes the stent to expand until it fits the inner wall of the vessel, conforming to contours as needed • the balloon is then deflated and drawn back •The stent stays in place permanently, holding the vessel open and improving the flow of blood.
  • 51. Angioplasty • a balloon catheter is passed through the guiding catheter to the area near the narrowing. A guide wire inside the balloon catheter is then advanced through the artery until the tip is beyond the narrowing. • the angioplasty catheter is moved over the guide wire until the balloon is within the narrowed segment. • balloon is inflated, compressing the plaque against the artery wall • once plaque has been compressed and the artery has been sufficiently opened, the balloon catheter will be deflated and removed.
  • 52. Bypass surgery  healthy blood vessel is removed from leg, arm or chest  blood vessel is used to create new blood flow path in your heart  the “bypass graft” enables blood to reach your heart by flowing around (bypassing) the blocked portion of the diseased artery. The increased blood flow reduces angina and the risk of heart attack.
  • 53.
  • 54. Lipid Management • All post MI patients should be on AMA step II diet ( < 7% of calories from saturated fats) • Post MI patients with LDL > 100 mg/dl are recommended to be on drug therapy to try to lower levels to <100 mg/dl • Recent data indicate that all MI patients should be on statin therapy, regardless of lipid levels or diet
  • 55. Long term Medications • Most oral medications instituted in the hospital at the time of MI are continued long term • Aspirin, beta blockers and statin are continued indefinitely • ACEI indefinitely in patients with CHF, ejection fraction <.40, hypertension, or diabetes